| Active substance | Mepolizumab |
| Holder | GSK Pharmaceuticals |
| Status | Closed |
| Indication | Eosionophylic granulomatosis with polyangitis (EGPA or churg-Strauss Syndrom) |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 24/07/2015 |
Mepolizumab®
Last updated on 10/09/2024